Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Check out the exclusive pitch deck Valerie Health used to raise $30 million from Redpoint Ventures to automate healthcare faxes - 2Pentagon advances Golden Dome missile defense with new Space Force contracts
- 3Sound and Delightful: 12 Nutritious Smoothie Recipes
- 4Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says
- 5Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- Sentimental tree to shine at Arctic League annual broadcast
- Shredded cheese recall: Multiple brands sold at Aldi, Target and Walmart affected over potential metal fragment contamination
- Vote in favor of your Number one natural product
- The EU Is Considering Lifting Tariffs on Chinese Electric Vehicles
- 25 Most Beautiful Villages in France You Can Actually Visit
- No red, no long shorts: The fashion rules Joe Burrows lives by
- SpaceX's 1st 'Version 3' Super Heavy Starship booster buckles under pressure during initial tests
- Vote In favor of Your #1 Method for diminishing Pressure
- The most effective method to Go with Informed Choices on Vehicle Leases
